Association of alprazolam with major cardiovascular events in patients with hypertension.

Journal of Evaluation in Clinical Practice
Chao-Bin YehSai-Wai Ho

Abstract

Anxiety is a mediator for emotional reactivity and acute blood pressure elevations, which are associated with an increased risk of cardiovascular death. Alprazolam is a common medication for anxiolysis. We hypothesized that alprazolam usage can reduce the risk of major adverse cardiovascular events (MACEs) in patients with hypertension. A retrospective cohort study was performed using datasets from Taiwanese Health and Welfare Data. Patients with hypertension were divided into exposed (Alprazolam-exposed) and control groups (non-Alprazolam-exposed) with 1:1 propensity score matching. The study endpoint was the occurrence of MACE. Adjusted hazard ratio (aHR) of MACE risk was estimated using the multiple Cox proportional hazard model. Age-stratified analysis was performed to evaluate the interaction of age and alprazolam use with MACEs. The study cohort consisted of 335 517 alprazolam-exposed patients and 1:1 PSM controls. The mean age was 63.62 ± 12.71 years in the Alprazolam-exposed population. Alprazolam exposure was significantly associated with reduced risk of MACEs (aHR = 0.965, 95% CI = 0.954-0.977), including ischemic stroke (aHR = 0.958, 95% CI = 0.940-0.976), hemorrhagic stroke (aHR = 0.856, 95% CI = 0.821-0.892), myoca...Continue Reading

References

Mar 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·J G EdwardsN S Rawson
Sep 7, 2002·The American Journal of Emergency Medicine·Toby L LitovitzBlaine E Benson
Jul 5, 2003·Stroke; a Journal of Cerebral Circulation·M J AriesenA Algra
Dec 25, 2003·International Journal of Clinical Pharmacology and Therapeutics·M VrecerA Mrhar
Jun 23, 2004·British Journal of Clinical Pharmacology·Geoffrey K IsbisterIan M Whyte
Sep 27, 2005·American Journal of Hypertension·Ehud GrossmanArie Shamiss
Oct 11, 2005·The American Journal of Cardiology·Richard FleetNancy Frasure-Smith
Apr 6, 2007·Health Technology Assessment : HTA·S WardN Payne
Jan 12, 2008·The American Journal of Medicine·Christopher O'ReganEdward J Mills
Jan 22, 2008·Journal of the American College of Cardiology·Franz H Messerli, Sripal Bangalore
Oct 15, 2013·Statistics in Medicine·Peter C Austin
Apr 23, 2014·The Canadian Journal of Cardiology·Laura M Kuyper, Nadia A Khan
May 16, 2014·Psychiatry and Clinical Neurosciences·Wei-Shih HuangChia-Hung Kao
Apr 26, 2015·American Journal of Hypertension·Beth E CohenIan M Kronish
Jun 22, 2016·The American Journal of Cardiology·Connor A EmdinBenjamin H M Hunn
Jun 29, 2016·Lancet·Michelle G Craske, Murray B Stein
Dec 14, 2016·Advances in Experimental Medicine and Biology·John M Cruickshank
Jan 18, 2017·JAMA : the Journal of the American Medical Association·Mohammad H ForouzanfarChristopher J L Murray
Jan 31, 2017·European Psychiatry : the Journal of the Association of European Psychiatrists·M Pérez-PiñarS Ayis
Aug 5, 2017·Journal of Addiction Medicine·Nassima Ait-DaoudDerek Blevins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.